<DOC>
	<DOC>NCT02020499</DOC>
	<brief_summary>This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.</brief_summary>
	<brief_title>Predictive Factors Study</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Diagnosis of Acromegaly. Males and females aged 18 years and older. Signed informed consent (patient must give consent to the collection of retrospective data). Patients who have had surgery may enter the study 3 months postsurgery and evaluated for the duration of the study. With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG. If already being treated with ATG: Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF1 levels at baseline and under treatment as applicable). Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly. The subject has had radiotherapy in the last 5 years. The subject has had surgery in the last 3 months. The subject has already been included in this study. Participation in an interventional trial, or receiving experimental drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>